Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

Research output: Contribution to journalArticle


  • Stella Bowcock
  • Tim Planche
  • Gulnaz Iqbal
  • Kwee Yong
  • Jill Wood
  • Kerry Raynes
  • Helen Higgins
  • Bryony Dawkins
  • David Meads
  • Claire T Hulme
  • Eric Low
  • Janet A Dunn

External organisations

  • Cancer Immunology and Immunotherapy Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • King’s College Hospital NHS Foundation Trust, London, UK
  • Institute of Infection and Immunity, St George’s Hospital, University of London, London, UK
  • Warwick Clinical Trials Unit, University of Warwick, Coventry
  • Departments of Cardiology, Sandwell and West Birmingham Hospitals NHS Trust and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Department of Haematology, University College London Cancer Institute
  • Academic Unit of Health Economics, University of Leeds, Leeds, UK; Health Economics Group, Institute of Health Research, University of Exeter Medical School, Exeter, UK.
  • School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham
  • Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
  • Patient Advocacy, Myeloma UK, Edinburgh, UK


Original languageEnglish
Pages (from-to)1-94
JournalHealth Technology Assessment
Issue number62
Publication statusPublished - Nov 2019